First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1 ; volume:28 ; number:10 ; day:7 ; month:8 ; year:2023 ; pages:1354-1368 ; date:10.2023
International journal of clinical oncology ; 28, Heft 10 (7.8.2023), 1354-1368, 10.2023

Classification: Medizin, Gesundheit

Creator: Nishio, Makoto
Ohe, Yuichiro
Ikeda, Satoshi
Yokoyama, Toshihide
Hayashi, Hidetoshi
Fukuhara, Tatsuro
Sato, Yuki
Tanaka, Hiroshi
Hotta, Katsuyuki
Sugawara, Shunichi
Daga, Haruko
Okamoto, Isamu
Kasahara, Kazuo
Naito, Tateaki
Li, Li
Gupta, Ravi G.
Bushong, Judith
Mizutani, Hideaki

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10147-023-02390-2

URN: urn:nbn:de:101:1-2023122316120834603058

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:23 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Nishio, Makoto
Ohe, Yuichiro
Ikeda, Satoshi
Yokoyama, Toshihide
Hayashi, Hidetoshi
Fukuhara, Tatsuro
Sato, Yuki
Tanaka, Hiroshi
Hotta, Katsuyuki
Sugawara, Shunichi
Daga, Haruko
Okamoto, Isamu
Kasahara, Kazuo
Naito, Tateaki
Li, Li
Gupta, Ravi G.
Bushong, Judith
Mizutani, Hideaki
SpringerLink (Online service)

Other Objects (12)

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Schriftgut

CHECK MATE.- Herbstübung

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Schriftgut

CHECK MATE.- Herbstübung

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Schriftgut

CHECK MATE.- Herbstübung

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

CHECK MATE.- Herbstübung

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

CHECK MATE.- Herbstübung

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

CHECK MATE.- Herbstübung

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Related objects

Reset password